Watch KYMR. Know when insiders buy.
One email the day a filing lands. Free.
Work order
34
FLAG · insiders 27, shorts 40
Insiders, 90 days
−$744K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $9.8BP/E —DIV YIELD —FCF YIELD -2.44%REV TTM $105M +134.8%NET INCOME −$299.6MNET CASH —52W 43.26 – 127.31SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $65M | +466.4% | 0.0% | −$75.6M | −$61.2M | — | -0.62 | −$54.1M | $473K | −$54.5M | Aug 5 |
| Q1 2026 · Mar 31 | $34.4M | +55.5% | 0.0% | −$84.2M | −$69.2M | — | -0.71 | −$88.8M | $434K | −$89.3M | Apr 30 |
| Q4 2025 · Dec 31derived | $2.9M | −61.2% | 0.0% | −$97.9M | −$87M | — | -0.98 | −$66.7M | $106K | −$66.9M | Feb 26 |
| Q3 2025 · Sep 30 | $2.8M | −26.1% | 0.0% | −$92.5M | −$82.2M | — | -0.94 | −$27.1M | $181K | −$27.3M | Nov 4 |
| Q2 2025 · Jun 30 | $11.5M | −55.3% | 0.0% | −$84.6M | −$76.6M | — | -0.95 | −$59.9M | $695K | −$60.6M | Aug 5 |
| Q1 2025 · Mar 31 | $22.1M | +114.8% | 0.0% | −$74.4M | −$65.6M | — | -0.82 | −$79.2M | $467K | −$79.6M | Apr 30 |
| Q4 2024 · Dec 31derived | $7.4M | −84.6% | 0.0% | −$80.8M | −$70.8M | — | -0.89 | −$61.8M | $936K | −$62.7M | Feb 26 |
| Q3 2024 · Sep 30 | $3.7M | −20.9% | 0.0% | −$72.1M | −$62.5M | — | -0.82 | −$50.2M | −$189K | −$50M | Nov 4 |
| Q2 2024 · Jun 30 | $25.6M | — | 0.0% | −$50.9M | −$42.1M | — | -0.58 | −$42.9M | $4.7M | −$47.6M | Aug 11 |
| Q1 2024 · Mar 31 | $10.3M | — | 0.0% | −$57.8M | −$48.6M | — | -0.69 | −$39.6M | $7.4M | −$47M | May 9 |
| Q4 2023 · Dec 31derived | $47.9M | — | — | −$19.3M | −$14.4M | — | -0.25 | $8M | $11.6M | −$3.6M | Feb 26 |
| Q3 2023 · Sep 30 | $4.7M | — | — | −$57.5M | −$52.9M | — | -0.90 | −$31.6M | $8.1M | −$39.7M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $39.2M | 0.0% | −$349.4M | −$311.4M | -794.0% | -3.69 | −$232.9M | $1.4M | −$234.3M | — | — |
| FY2024 · to Dec 31 | $47.1M | 0.0% | −$261.6M | −$223.9M | -475.6% | -2.98 | −$194.5M | $12.8M | −$207.3M | — | — |
| FY2023 · to Dec 31 | $78.6M | 0.0% | −$165.5M | −$147M | -187.0% | -2.52 | −$102.8M | $34.5M | −$137.3M | — | — |
| FY2022 · to Dec 31 | $46.8M | 0.0% | −$161.3M | −$154.8M | -330.6% | -2.87 | −$153.1M | $2.8M | −$155.9M | — | — |
| FY2021 · to Dec 31 | $72.8M | — | −$100.5M | −$100.2M | -137.6% | -2.09 | −$128.9M | $1.6M | −$130.5M | — | — |
| FY2020 · to Dec 31 | $34M | — | −$46.3M | −$45.6M | -134.0% | -3.15 | $88.1M | $9.1M | $79M | — | — |
Every number comes from Kymera Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.